About Genocea Biosciences (NASDAQ:GNCA)
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections. The company is also develops GEN-009, which is in pre-clinical stage to treat neoantigen cancer; GEN-010 that is in pre-clinical stage for the treatment of patients in second generation neoantigen cancer; GEN-007, which is in research stage to Epstein-Barr virus; and GEN-006 that is in research stage for the treatment of immune-oncology-tumor-associated antigen cancer. It license agreement with University of California and Harvard University; and collaboration agreement with Novavax, Inc. Genocea Biosciences, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GNCA
CUSIPN/A
Phone617-876-8191
Debt
Debt-to-Equity Ratio-1.26%
Current Ratio0.83%
Quick Ratio0.83%
Price-To-Earnings
Trailing P/E Ratio-0.44
Forward P/E Ratio-1.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$230,000.00
Price / Sales308.80
Cash FlowN/A
Price / CashN/A
Book Value($0.07) per share
Price / Book-12.36
Profitability
EPS (Most Recent Fiscal Year)($1.98)
Net Income$-56,710,000.00
Net MarginsN/A
Return on Equity-454.50%
Return on Assets-157.78%
Miscellaneous
Employees52
Outstanding Shares82,100,000
Genocea Biosciences (NASDAQ:GNCA) Frequently Asked Questions
What is Genocea Biosciences' stock symbol?
Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."
How were Genocea Biosciences' earnings last quarter?
Genocea Biosciences (NASDAQ:GNCA) released its quarterly earnings results on Friday, February, 16th. The biotechnology company reported ($0.37) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.03. View Genocea Biosciences' Earnings History.
When is Genocea Biosciences' next earnings date?
What price target have analysts set for GNCA?
7 brokerages have issued twelve-month price targets for Genocea Biosciences' stock. Their forecasts range from $2.50 to $10.00. On average, they expect Genocea Biosciences' share price to reach $4.7857 in the next twelve months. View Analyst Ratings for Genocea Biosciences.
What are Wall Street analysts saying about Genocea Biosciences stock?
Here are some recent quotes from research analysts about Genocea Biosciences stock:
- 1. According to Zacks Investment Research, "Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections, GEN-004 and HSV-2 prophylaxis and malaria. Genocea Biosciences, Inc. is headquartered in Cambridge, Massachusetts. " (4/18/2018)
- 2. Cantor Fitzgerald analysts commented, "GNCA shares could experience some weakness on the news of the departure of the CFO, Jonathan Poole, who resigned effective 3/23, to pursue other opportunities." (3/11/2018)
Are investors shorting Genocea Biosciences?
Genocea Biosciences saw a increase in short interest during the month of March. As of March 29th, there was short interest totalling 3,812,145 shares, an increase of 72.8% from the March 15th total of 2,205,903 shares. Based on an average daily trading volume, of 1,103,972 shares, the days-to-cover ratio is presently 3.5 days. Approximately 8.8% of the shares of the company are sold short.
Who are some of Genocea Biosciences' key competitors?
Some companies that are related to Genocea Biosciences include Pluristem Therapeutics (PSTI), Organovo (ONVO), Lorus Therapeutics (APTO), Eiger Biopharmaceuticals (EIGR), Aevi Genomic Medicine (GNMX), Curis (CRIS), Applied Genetic Technologies (AGTC), Cidara Therapeutics (CDTX), aTyr Pharma (LIFE), Brainstorm Cell Therapeutics (BCLI), TRACON Pharmaceuticals (TCON), CytRx (CYTR), Proteon Therapeutics (PRTO), Vaxart (VXRT), Vical (VICL), Microbot Medical (MBOT), Neuralstem (CUR) and Oncobiologics (ONS).
Who are Genocea Biosciences' key executives?
Genocea Biosciences' management team includes the folowing people:
- Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 49)
- Dr. George R. Siber M.D., Ph.D., Chairman of Scientific Advisory Board & Exec. Director (Age 73)
- Dr. Darren Higgins Ph.D., Scientific Co-Founder and Member of Scientific Advisory Board
- Dr. Jessica Baker Flechtner, Chief Scientific Officer (Age 46)
- Mr. Eric S. Hoffman, Chief Bus. Officer (Age 48)
Has Genocea Biosciences been receiving favorable news coverage?
News headlines about GNCA stock have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Genocea Biosciences earned a daily sentiment score of 0.19 on Accern's scale. They also assigned press coverage about the biotechnology company an impact score of 46.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Genocea Biosciences?
Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Genocea Biosciences' stock price today?
One share of GNCA stock can currently be purchased for approximately $0.8651.
How big of a company is Genocea Biosciences?
Genocea Biosciences has a market capitalization of $72.78 million and generates $230,000.00 in revenue each year. The biotechnology company earns $-56,710,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Genocea Biosciences employs 52 workers across the globe.
How can I contact Genocea Biosciences?
Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The biotechnology company can be reached via phone at 617-876-8191 or via email at [email protected]
MarketBeat Community Rating for Genocea Biosciences (GNCA)
MarketBeat's community ratings are surveys of what our community members think about Genocea Biosciences and other stocks. Vote "Outperform" if you believe GNCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Genocea Biosciences (NASDAQ:GNCA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Genocea Biosciences in the last 12 months. Their average twelve-month price target is $4.7857, suggesting that the stock has a possible upside of 453.20%. The high price target for GNCA is $10.00 and the low price target for GNCA is $2.50. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.86 | 2.86 | 2.60 | 2.60 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $4.7857 | $4.7857 | $7.3750 | $11.90 |
| Price Target Upside: | 453.20% upside | 285.94% upside | 535.78% upside | 124.11% upside |
Genocea Biosciences (NASDAQ:GNCA) Consensus Price Target History
Genocea Biosciences (NASDAQ:GNCA) Analyst Ratings History
Show:
(Data available from 4/21/2016 forward)
Genocea Biosciences (NASDAQ:GNCA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Genocea Biosciences (NASDAQ GNCA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 10.29%
Genocea Biosciences (NASDAQ GNCA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/17/2018 | William D Clark | CEO | Buy | 25,000 | $0.80 | $20,000.00 | 82,931 |  |
| 7/24/2017 | Jonathan Poole | CFO | Sell | 45,000 | $6.00 | $270,000.00 | 84,247 | |
| 11/8/2016 | Eric S. Hoffman | Insider | Buy | 7,000 | $3.49 | $24,430.00 | | |
| 11/7/2016 | Jonathan Poole | CFO | Buy | 7,000 | $3.34 | $23,380.00 | | |
| 11/7/2016 | William D. Clark | Insider | Buy | 2,800 | $3.49 | $9,772.00 | | |
| 5/9/2016 | Jonathan Poole | CFO | Buy | 4,000 | $3.88 | $15,520.00 | 8,213 | |
| 12/16/2015 | William D Clark | CEO | Buy | 3,800 | $6.45 | $24,510.00 | 43,607 | |
| 9/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $11.35 | $25,299.15 | 1,881 | |
| 6/19/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 30,004 | $13.04 | $391,252.16 | | |
| 6/17/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 10,618 | $13.01 | $138,140.18 | | |
| 6/16/2015 | Polaris Venture Management Co. | Major Shareholder | Sell | 46,000 | $13.24 | $609,040.00 | | |
| 6/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.52 | $23,449.08 | | |
| 5/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,229 | $10.21 | $22,758.09 | | |
| 4/1/2015 | Jessica Baker Flechtner | VP | Sell | 2,283 | $11.77 | $26,870.91 | | |
| 3/17/2015 | Stephen J Hoffman | Director | Buy | 700,000 | $8.25 | $5,775,000.00 | | |
| 2/2/2015 | Jessica Baker Flechtner | VP | Sell | 4,699 | $8.50 | $39,941.50 | | |
| 9/12/2014 | Jessica Baker Flechtner | VP | Sell | 6,435 | $12.00 | $77,220.00 | | |
| 9/11/2014 | Paul Giannasca | VP | Sell | 4,071 | $11.84 | $48,200.64 | | |
| 9/10/2014 | Paul Giannasca | VP | Sell | 834 | $12.35 | $10,299.90 | | |
| 9/9/2014 | Paul Giannasca | VP | Sell | 2,455 | $12.43 | $30,515.65 | | |
| 9/8/2014 | Paul Giannasca | VP | Sell | 2,970 | $12.80 | $38,016.00 | | |
| 8/29/2014 | Paul Giannasca | VP | Sell | 6,760 | $12.50 | $84,500.00 | | |
| 8/14/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 9,660 | $13.01 | $125,676.60 | | |
| 8/12/2014 | Polaris Venture Management Co. | Major Shareholder | Sell | 63,794 | $13.28 | $847,184.32 | | |
| 2/10/2014 | Plc Glaxosmithkline | Insider | Buy | 143,773 | $12.00 | $1,725,276.00 | | |
| 2/10/2014 | Polaris Venture Management Co. | Major Shareholder | Buy | 232,820 | $12.00 | $2,793,840.00 | | |
| 2/10/2014 | Stephen J Hoffman | Director | Buy | 250,931 | $12.00 | $3,011,172.00 | | |
(Data available from 1/1/2013 forward)
Genocea Biosciences (NASDAQ GNCA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Genocea Biosciences (GNCA) Highlights Data from ATLAS Platform at 2018 AACR Meetings
www.streetinsider.com - April 19 at 8:16 AM |
 | Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods
finance.yahoo.com - April 18 at 5:45 PM |
 | Genocea Biosciences (GNCA) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:41 AM |
| Head-To-Head Review: Genocea Biosciences (GNCA) & Biogen (BIIB)
www.americanbankingnews.com - April 18 at 1:30 AM |
| Genocea Biosciences (GNCA) Upgraded to "Hold" by ValuEngine
www.americanbankingnews.com - April 16 at 7:34 PM |
| ValuEngine Downgrades Genocea Biosciences (GNCA) to Sell
www.americanbankingnews.com - April 14 at 1:59 PM |
| Short Interest in Genocea Biosciences Inc (GNCA) Increases By 72.8%
www.americanbankingnews.com - April 13 at 2:10 AM |
| Genocea Biosciences Inc (GNCA) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 8:49 AM |
| -$0.14 EPS Expected for Genocea Biosciences Inc (GNCA) This Quarter
www.americanbankingnews.com - April 12 at 1:13 AM |
| Contrasting Genocea Biosciences (GNCA) and TrovaGene (TROV)
www.americanbankingnews.com - April 8 at 10:15 AM |
| Genocea Biosciences (GNCA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 31 at 11:09 AM |
| Genocea Biosciences Inc (GNCA) Short Interest Up 66.5% in March
www.americanbankingnews.com - March 30 at 3:38 AM |
| Genocea Biosciences Inc (GNCA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 8:54 AM |
 | Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences ... - Nasdaq
www.nasdaq.com - March 13 at 8:26 AM |
 | Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing - GlobeNewswire (press release)
www.globenewswire.com - March 13 at 8:26 AM |
| Genocea Biosciences Inc (GNCA) Short Interest Update
www.americanbankingnews.com - March 13 at 1:08 AM |
| Genocea Appoints Narinder Singh as SVP Pharmaceutical Sciences & Manufacturing
finance.yahoo.com - March 12 at 6:39 PM |
| Cantor Fitzgerald Reiterates Buy Rating for Genocea Biosciences (GNCA)
www.americanbankingnews.com - March 11 at 8:18 PM |
| Genocea Biosciences Inc Forecasted to Post FY2018 Earnings of ($0.59) Per Share (GNCA)
www.americanbankingnews.com - March 9 at 10:35 AM |
| HC Wainwright Begins Coverage on Genocea Biosciences (GNCA)
www.americanbankingnews.com - March 8 at 11:40 PM |
| HC Wainwright Takes Bullish Stance On Two Cancer-Focused Pharma Companies
finance.yahoo.com - March 8 at 6:43 PM |
| Cantor Fitzgerald Initiates Coverage on Genocea Biosciences (GNCA)
www.americanbankingnews.com - March 5 at 7:20 PM |
| Genocea to Present at Two March Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 5 at 8:17 AM |
| Genocea to Present at Two March Investor Conferences
finance.yahoo.com - March 5 at 8:17 AM |
| Genocea Biosciences Inc (NASDAQ:GNCA): Does The -14.40% Earnings Decline Make It An Underperformer?
finance.yahoo.com - February 24 at 8:15 AM |
| Genocea Biosciences Inc (GNCA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 21 at 7:36 AM |
| Genocea Biosciences Inc (GNCA) Expected to Announce Earnings of -$0.20 Per Share
www.americanbankingnews.com - February 20 at 3:08 AM |
| Genocea Biosciences (GNCA) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - February 16 at 11:40 AM |
| Genocea Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - February 15 at 9:29 AM |
| Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 15 at 9:29 AM |
| Genocea Biosciences (GNCA) Appoints Ali Behbahani M.D. to Board
www.streetinsider.com - February 13 at 9:58 AM |
| NEA Partner Ali Behbahani, M.D. Joins Genocea Biosciences’ Board of Directors
finance.yahoo.com - February 13 at 9:58 AM |
| Genocea Biosciences (GNCA) Earns Outperform Rating from Analysts at Robert W. Baird
www.americanbankingnews.com - February 12 at 9:00 PM |
| Short Interest in Genocea Biosciences Inc (GNCA) Grows By 73.9%
www.americanbankingnews.com - February 9 at 4:58 PM |
| Genocea to Host Fourth Quarter and Year End 2017 Financial Results Conference Call & Webcast on February 15, 2018 at 9 a.m. ET
finance.yahoo.com - February 8 at 8:11 AM |
| Genocea Biosciences (GNCA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - February 7 at 2:14 AM |
| Genocea Biosciences (GNCA) Upgraded by Needham & Company LLC to "Buy"
www.americanbankingnews.com - February 6 at 11:30 PM |
 | Genocea Biosciences: 200% Dilution, Hopelessness And Anger ... - Seeking Alpha
seekingalpha.com - February 3 at 9:30 AM |
| Analysts Anticipate Genocea Biosciences Inc (GNCA) to Post -$0.38 Earnings Per Share
www.americanbankingnews.com - February 3 at 3:12 AM |
| Genocea Biosciences Inc (GNCA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 9:04 AM |
| Genocea Biosciences Inc (GNCA) CEO William D. Clark Acquires 25,000 Shares
www.americanbankingnews.com - January 19 at 4:46 PM |
| Genocea Biosciences, Inc. Announces Proposed Concurrent Public ... - GlobeNewswire (press release)
globenewswire.com - January 18 at 4:55 PM |
| Genocea Biosciences (GNCA) Prices $55M Concurrent Public Offerings - StreetInsider.com
www.streetinsider.com - January 18 at 4:55 PM |
| Genocea Biosciences (GNCA) Prices $55M Concurrent Public Offerings
www.streetinsider.com - January 17 at 5:30 PM |
| Genocea Biosciences, Inc. Announces Pricing of $55 Million Concurrent Public Offerings
finance.yahoo.com - January 17 at 9:17 AM |
| Brokerages Expect Genocea Biosciences Inc (GNCA) to Announce -$0.38 EPS
www.americanbankingnews.com - January 17 at 5:12 AM |
| Genocea Biosciences, Inc. Announces Proposed Concurrent Public Offerings of Common Stock and Class A Warrants and Series A Convertible Preferred Stock and Class A Warrants
finance.yahoo.com - January 16 at 5:18 PM |
| Critical Review: Genocea Biosciences (GNCA) & The Competition
www.americanbankingnews.com - January 10 at 8:02 AM |
| How Do Analysts See Genocea Biosciences Inc (NASDAQ:GNCA) Performing Over The Couple Of Years?
finance.yahoo.com - January 3 at 5:24 PM |
| Glancy Prongay & Murray Reminds Investors of the January 2, 2018 Deadline in the Class Action Lawsuit Against Genocea Biosciences, Inc. (GNCA)
finance.yahoo.com - January 2 at 6:45 PM |
Genocea Biosciences (NASDAQ:GNCA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Genocea Biosciences (NASDAQ:GNCA) Income Statement, Balance Sheet and Cash Flow Statement
Genocea Biosciences (NASDAQ GNCA) Stock Chart for Saturday, April, 21, 2018
Loading chart…
